3062-53-1

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-bromoethoxy)-1-chloro-4-nitrobenzene is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be further modified and incorporated into drug molecules, contributing to the development of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(2-bromoethoxy)-1-chloro-4-nitrobenzene is utilized as a precursor in the production of agrochemicals, such as pesticides and herbicides, due to its potential to be transformed into active ingredients with specific pesticidal properties.
Used in Organic Synthesis:
2-(2-bromoethoxy)-1-chloro-4-nitrobenzene serves as a valuable building block in organic synthesis, allowing chemists to create a wide range of organic compounds through various chemical reactions, expanding the scope of chemical research and development.
It is crucial to handle and use 2-(2-bromoethoxy)-1-chloro-4-nitrobenzene with care, as it can be toxic and pose potential risks to human health and the environment if not managed properly.

Upstream product

• 619-10-3 5-nitro-2-chlorophenol 
• 106-93-4 ethylene dibromide 
• 1009-36-5 2-chloro-5-nitroanisole 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 1453211-72-7 1-[2-(2-chloro-5-nitrophenoxy)ethyl]-1H-pyrazole 
• 1453211-73-8 (3R,5S)-3,5-dimethyl-1-{4-nitro-2-[2-(1H-pyrazol-1-yl)ethoxy]phenyl}piperazine 
• 758711-93-2 2-(2-(2-Chloro-5-nitro-phenoxy)-ethyl)-1-(2-(3,4-dimethoxy-phenyl)-ethyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline 
• 31185-43-0 1-(2-Chlor-5-nitrophenoxy)-2-(4-fluorsulfonyl-phenoxy)-ethan 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors

Inhibition of the VEGF signaling pathway has become a valuable approach in the treatment of cancers. Guided by X-ray crystallography and molecular modeling, a series of 2-aminobenzimidazoles and 2-aminobenzoxazoles were identified as potent inhibitors of VEGFR-2 (KDR) in both enzymatic and HUVEC cellular proliferation assays. In this report we describe the synthesis and structure-activity relationship of a series of 2-aminobenzimidazoles and benzoxazoles, culminating in the identification of benzoxazole 22 as a potent and selective VEGFR-2 inhibitor displaying a good pharmacokinetic profile. Compound 22 demonstrated efficacy in both the murine matrigel model for vascular permeability (79% inhibition observed at 100 mg/kg) and the rat corneal angiogenesis model (ED50 = 16.3 mg/kg).

Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists

The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.